Identification of phosphate transporter NaPi2b as MX35 cancer antigen by modified SEREX approach [PDF]
Biopolymers and Cell, 2008 In this study we describe the identification of sodium-dependent phosphate transporter NaPi2b as MX35 cancer-associated antigen. To achieve this goal we have screened extensively a cDNA expressing library from ovarian cancer cell line OVCAR3 with ...
Ramziya Kiyamova +9 more
core +5 more sources
Inhibition of sodium-dependent phosphate transporter NaPi2b function with MX35 antibody [PDF]
Biopolymers and Cell, 2011 Sodium-dependent phosphate transporter NaPi2b is involved in transport of inorganic phosphate and the maintenance of phosphate homeostasisin human body. NaPi2b wasrecently identified as a marker of ovarian cancer, termed MX35.
Vitalina Gryshkova +2 more
core +5 more sources
Targeting NaPi2b in ovarian cancer. [PDF]
Cancer Treatment Reviews, 2023 Novel biomarkers are needed to direct new treatments for ovarian cancer, a disease for which the standard of care remains heavily focused on platinum-based chemotherapy.
Banerjee, S +3 more
core +6 more sources
Recognition of the sodium-dependent phosphate transporter NaPi2b by monoclonal antibodies N-NaPi2b in ovarian cancer cells [PDF]
Учёные записки Казанского университета: Серия Естественные науки, 2020 The sodium-dependent phosphate cotransporter NaPi2b encoded by the SLC34A2 gene is a transmembrane protein that belongs to the family of phosphate transporters SLC34 and is involved in maintaining phosphate homeostasis in the human body.
L.F. Minigulova +10 more
doaj +2 more sources
Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b [PDF]
BMC Cancer, 2017 Background To characterize the expression of the membrane transporter NaPi2b and antigen targeted by the MX35 antibody in ovarian tumor samples. The current interest to develop monoclonal antibody based therapy of ovarian cancer by targeting NaPi2b ...
Kristina Levan +5 more
doaj +4 more sources
PBPK Modeling to Predict Clinical Drug–Drug Interaction and Impact of Hepatic Impairment for an ADC With the Payload Auristatin F‐Hydroxypropylamide [PDF]
CPT: Pharmacometrics & Systems PharmacologyUpifitamab rilsodotin—an antibody drug conjugate (ADC)—comprises a NaPi2b‐targeted antibody conjugated to an auristatin‐based payload (auristatin F‐hydroxypropylamide [AF‐HPA]). AF‐HPA is metabolized by cytochrome P450 3A4 (CYP3A4) and, to a lower extent,
Niyanta Kumar +8 more
doaj +2 more sources
ADC: a deadly killer of platinum resistant ovarian cancer [PDF]
Journal of Ovarian ResearchPlatinum is a key component of ovarian cancer systemic therapy. However, most patients will eventually face a recurrence, leading to chemotherapy resistance, especially against platinum.
Xu Cheng +4 more
doaj +2 more sources
Uncovering potential targets for antibody-drug conjugates in the treatment of gynecologic malignancies [PDF]
Frontiers in PharmacologyBackgroundAntibody-drug conjugates (ADCs) play an important role in the targeted therapy of gynecological malignancies. The purpose of this study was to investigate the expression of targets in gynecologic malignancies in order to predict the selection ...
Yuying Jiang +6 more
doaj +2 more sources
Antibody therapeutics for epithelial ovarian cancer. [PDF]
Expert Opin Biol Ther, 2022 INTRODUCTION: High-grade serous ovarian carcinoma (HGSC) is an aggressive subtype of epithelial ovarian carcinoma (EOC) and remains the most lethal gynecologic cancer.
Ruiz M, Zhang N, Sood AK, An Z.
europepmc +3 more sources
Emerging role of mucins in antibody drug conjugates for ovarian cancer therapy. [PDF]
J Ovarian ResOvarian cancer stands as the deadliest gynecologic malignancy, responsible for nearly 65% of all gynecologic cancer-related deaths. The challenges in early detection and diagnosis, coupled with the widespread intraperitoneal spread of cancer cells and ...
Malik S +6 more
europepmc +3 more sources